DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)

11.94 0.25 (2.14%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NKTR $11.94 2.14%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $11.55
Previous Close $11.69
Daily Range $10.70 - $12.03
52-Week Range $9.16 - $17.55
Market Cap $1.6B
P/E Ratio -20.88
Dividend (Yield) $0.00 (0.0%)
Volume 6,493,538
Average Daily Volume 2,017,894
Current FY EPS -$0.58

Sector

Healthcare

Industry

Drug Makers

Nektar Therapeutics (NKTR) Description

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines. Website: http://www.nektar.com/

News & Commentary

Why Nektar Therapeutics Skyrocketed 30% Higher in October

An analyst day filled with good news gets shares of this beaten down biotech moving.

Nektar Therapeutics is Now Oversold (NKTR)

Commit To Purchase Nektar Therapeutics At $8, Earn 7.9% Annualized Using Options

Nektar Therapeutics Going Into The Decline With A Better Profile

Nektar Therapeutics Breaks Below 200-Day Moving Average - Notable for NKTR

Benzinga's Top Initiations

First Trust NYSE Arca Biotechnology Index Fund Experiences Big Outflow

After Hours Most Active for Jan 15, 2016 : EXR, MSCC, DYAX, BAC, NKTR, ATW, EPR, NBIX, CLDX, NVAX,

After Hours Most Active for Jan 15, 2016 : EXR, MSCC, DYAX, BAC, NKTR, ATW, EPR, NBIX, CLDX, NVAX, BX, HPE

Stocks Hitting 52-Week Highs

Baxalta's Adynovate Positive in Phase III Pediatric Study

Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-

Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

See More NKTR News...

NKTR's Top Competitors

NKTR $11.94 (2.14%)
Current stock: NKTR
TMO $123.18 (-3.62%)
Current stock: TMO
ILMN $136.05 (-5.11%)
Current stock: ILMN
WAT $115.47 (-2.08%)
Current stock: WAT